相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
David Gonzalez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M. Lokhorst et al.
BLOOD (2010)
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
Kai Neben et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
Laurence Lode et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan et al.
LANCET (2010)
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Donna Reece et al.
BLOOD (2009)
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Stefan Knop et al.
BLOOD (2009)
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
John D. Shaughnessy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context
Laura Chiecchio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
Wei Xiong et al.
BLOOD (2008)
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Bart Barlogie et al.
BLOOD (2008)
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma
Matthew W. Jenner et al.
BLOOD (2007)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma
Brian A. Walker et al.
BLOOD (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma
L. Chiecchio et al.
LEUKEMIA (2006)
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
H Chang et al.
BLOOD (2005)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
R Fonseca et al.
BLOOD (2003)